Navigation Links
Maryland Approves Medicaid Reimbursement for ActiPatch(R)
Date:4/21/2008

Other States May Soon Follow

FREDERICK, Md., April 21 /PRNewswire/ -- Maryland Medicaid has approved medical necessity product reimbursement for ActiPatch(TM) for kidney-compromised patients. BioElectronics Corporation, (Pink Sheets: BIEL), is the maker of ActiPatch, a revolutionary drug-free anti-inflammatory patch which accelerates healing.

Many commonly used pharmaceutical agents including aspirin, ibuprofen (Advil, Motrin, Nuprin) and Naproxen (Aleve, Anaprox, Naprosyn) with regular use and most especially long-term use, can have serious complications such as ulcers and bleeding from the gastrointestinal tract. These medications have been known to worsen cardiovascular conditions, increase high blood pressure, kidney disease and diabetes.

Andrew J. Whelan, CEO of BioElectronics Corporation, explains, "ActiPatch with its non-invasive, very efficient treatment for swelling and pain while accelerating recovery is the medicine of the future available today. We are actively pursuing additional reimbursement approvals nationally. ActiPatch is an important product that not only works without side-effects, it also has the potential to help keep medical costs down at a time when medical and insurance costs appear to be spiraling out of control," adds Whelan.

ActiPatch(TM) is a wafer thin patch with an embedded battery operated microchip that delivers weeks of continuous pulsed RF therapy for less than a dollar a day. The unique ActiPatch(TM) delivery system, using patented technology, provides a cost-effective, home use method to reduce soft tissue pain and swelling.

ActiPatch has regulatory clearance by the FDA for the treatment of edema following blepharoplasty.

For more information visit http://www.bioelectronicscorp.com or call 866-757-2284.

About BioElectronics

BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch is a drug free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling.

For more information visit: http://www.bioelectronicscorp.com.

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Media Relations Contact:

Patricia Baker, The Big Picture Agency LLC

Voice: 413-623-0950 ext. 221, email: pbaker@bigpictureagency.com

Investor Relations Contact:

Joe Noel, Emerging Growth Research LLP

Voice: 925-922-2560, email: jnoel701@yahoo.com


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpace Career Fair in Bethesda, Maryland Draws Hundreds of Industry Professionals
2. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
3. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
4. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
5. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
6. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
7. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
8. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
9. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
10. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
11. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)...  ArmaGen, Inc., today announced that it has ... executive officer, as well as a member of ... more than 17 years of executive management experience ... and pharmaceuticals. "Mathias is a ... skillset necessary to lead ArmaGen to its next ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... innovators, engineers, and scientists from around the world, was today awarded the "Best ... program is based entirely on merit and decided upon by a dedicated team ...
(Date:1/19/2017)... , Jan. 18, 2017 The ... reach USD 92.9 billion by 2025, according to ... Pharmaceutical industry has been adaptive of the function ... early as 2002. Among the services outsourced, clinical ... For instance, Johnson & Johnson was the first ...
(Date:1/19/2017)... LAKES, N.J. , Jan. 18, 2017 BD (Becton, ... technology company, announced today that it will host a live webcast ... at 1 p.m. (ET). The webcast can be ... be available for replay through Tuesday, January 31, 2017. ... About BD BD ...
Breaking Biology Technology:
(Date:12/22/2016)... , December 22, 2016 SuperCom (NASDAQ: ... secure solutions for the e-Government, Public Safety, HealthCare, and Finance sectors ... SuperCom, has been selected to implement and deploy a community-based supportive ... Northern California , further expanding its presence in the ... This new ...
(Date:12/16/2016)... DUBLIN , Dec 16, 2016 Research ... Access System Market - Global Forecast to 2021" report to ... ... projected to grow at a CAGR of 14.06% from 2016 to ... 2016, and is projected to reach 854.8 Million by 2021. The ...
(Date:12/15/2016)... , Dec. 15, 2016 Advancements ... experience, health wellness and wellbeing (HWW), and ... in three new passenger vehicles begin to ... gesture recognition, heart beat monitoring, brain wave ... facial monitoring, and pulse detection. These will ...
Breaking Biology News(10 mins):